RU2094059C1 - Method of transport of neurotropic preparation to brain - Google Patents
Method of transport of neurotropic preparation to brain Download PDFInfo
- Publication number
- RU2094059C1 RU2094059C1 RU93043262A RU93043262A RU2094059C1 RU 2094059 C1 RU2094059 C1 RU 2094059C1 RU 93043262 A RU93043262 A RU 93043262A RU 93043262 A RU93043262 A RU 93043262A RU 2094059 C1 RU2094059 C1 RU 2094059C1
- Authority
- RU
- Russia
- Prior art keywords
- neurotropic
- brain
- transport
- preparation
- drug
- Prior art date
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Изобретение относится к области биологии, а именно к способам транспорта нейротропных препаратов, например, [CH3CONH(CH2)3SO3]2Ca АОТА, в мозг.The invention relates to the field of biology, and in particular to methods of transporting neurotropic drugs, for example, [CH 3 CONH (CH 2 ) 3 SO 3 ] 2 Ca AOTA, to the brain.
Известный способ транспорта АОТА в мозг заключается во введении препарата в физиологическом растворе в кровоток [1]
Однако этот способ обладает низкой эффективностью, так как не обеспечивает подавления действия агентов, вызывающих судороги, а лишь увеличивает латентный период до наступления судорог.A known method of transporting AOTA to the brain is the introduction of the drug in physiological saline into the bloodstream [1]
However, this method has low efficiency, since it does not suppress the action of agents that cause seizures, but only increases the latent period before the onset of seizures.
Задача изобретения изыскание такого способа транспорта нейротропных препаратов в мозг, который бы позволил не только увеличить латентный период до наступления судорог, но и предотвратить их наступление. Для решения этой задачи предложен способ транспорта нейротропных препаратов в мозг, заключающийся в том, что в качестве транспортного средства используют конъюгаты циклодекстринов с полиэтиленоксидом общей формулы
где n 6 12;
m 6-7.The objective of the invention is the search for such a method of transporting neurotropic drugs to the brain, which would not only increase the latent period before the onset of seizures, but also prevent their onset. To solve this problem, a method for the transport of neurotropic drugs to the brain is proposed, which consists in the use of conjugates of cyclodextrins with polyethylene oxide of the general formula
where
m 6-7.
Водный раствор конъюгата и нейротропного препарата с концентрацией препарата 0,01-0,1 г/мл вводят в кровоток. An aqueous solution of the conjugate and neurotropic drug with a concentration of the drug of 0.01-0.1 g / ml is injected into the bloodstream.
Концентрация препарата менее 0,01 г/мл не дает эффекта, а при концентрации более 0,1 г/мл увеличивается токсичность. Эффективность описанных конъюгатов в качестве транспортного средства не могла быть предсказана заранее, так как они обладают сложной пространственной структурой. Скорее всего их успешное применение связано с сочетанием в них способности солюбилизации и мембранотропных свойств, что и обеспечило перенос нейротропных препаратов через биологические мембраны. The concentration of the drug less than 0.01 g / ml does not give an effect, and at a concentration of more than 0.1 g / ml toxicity increases. The effectiveness of the described conjugates as a vehicle could not be predicted in advance, since they have a complex spatial structure. Most likely, their successful use is associated with a combination of the solubilization ability and membrane-active properties in them, which ensured the transfer of neurotropic drugs through biological membranes.
Эффективность предложенного способа проверялась в опытах in vivo на белых мышах. В качестве препарата, вызывающего судороги, применялся коразол. Регистрировалась продолжительность латентного периода до наступления судорог. При статистической обработке результатов использовали критерий Стьюденста. The effectiveness of the proposed method was tested in in vivo experiments on white mice. As a drug that causes seizures, corazole was used. The duration of the latent period before the onset of seizures was recorded. For statistical processing of the results, the Student test was used.
Пример 1. Готовят раствор, содержащий 0,18 г конъюгата β-циклодекстрина с полиэтиленоксидом (n 12, мол. масса 4900) и 0,015 г АОТА в 1 мл воды. Этот раствор в количестве 0,2 мл вводят внутривенно группе из шести белых мышей самцов линии L весом 18-20 г. Через 1 ч после введения препарата внутрибрюшинно вводят препарат, вызывающий судороги коразол (0,3 мл 1%-ного раствора) и регистрируют латентный период до наступления судорог. Example 1. A solution is prepared containing 0.18 g of a conjugate of β-cyclodextrin with polyethylene oxide (n 12, mol. Mass 4900) and 0.015 g of AOTA in 1 ml of water. This solution in an amount of 0.2 ml is administered intravenously to a group of six white mice of male L-line weighing 18-20 g. 1 h after administration of the drug, a drug causing convulsions of corazole is injected intraperitoneally (0.3 ml of a 1% solution) and recorded latent period before convulsions.
Результат испытаний приведен в таблице. The test result is shown in the table.
Пример 2. Готовят раствор, содержащий 0,56 г конъюгата, описанного в примере 1, и 0,030 АОТА в 1 мл. Далее испытание проводят по методике примера 1. Example 2. A solution is prepared containing 0.56 g of the conjugate described in Example 1 and 0.030 AOTA in 1 ml. Next, the test is carried out according to the method of example 1.
Результат испытаний приведен в таблице. The test result is shown in the table.
Пример 3. Испытания проводят по методике примера 1, но используют конъюгат b-циклодекстрина с полиэтиленоксидом с молекулярной массой 3000 и n 6. Example 3. The tests are carried out according to the method of example 1, but using a conjugate of b-cyclodextrin with polyethylene oxide with a molecular weight of 3000 and
Результат испытаний приведен в таблице. The test result is shown in the table.
Пример 4. Испытания проводят по методике примера 1, но берут конъюгат b-циклодекстрина с полиэтиленоксидом с молекулярной массой 4200 и п 10. Example 4. The tests are carried out according to the method of example 1, but take the conjugate of b-cyclodextrin with polyethylene oxide with a molecular weight of 4200 and p 10.
Результат испытаний приведен в таблице. The test result is shown in the table.
Пример 5. Испытания проводят по методике примера 1, но берут 0,01 г АОТА в 1 мл водного раствора. Example 5. The tests are carried out according to the method of example 1, but take 0.01 g of AOTA in 1 ml of an aqueous solution.
Результат испытаний приведен в таблице. The test result is shown in the table.
Пример 6. Испытания проводят по методике примера 4, но берут АОТА в количестве 0,1 г в 1 мл водного раствора. Example 6. The tests are carried out according to the method of example 4, but take AOTA in the amount of 0.1 g in 1 ml of an aqueous solution.
Результат испытаний приведен в таблице. The test result is shown in the table.
Таким образом, предлагаемый способ позволяет не только увеличить латентный период коразоловых судорог, но в ряде случаев даже их предотвратить. Thus, the proposed method allows not only to increase the latent period of corazole seizures, but in some cases even to prevent them.
Claims (1)
где n 6 12;
m 6 7,
причем концентрация нейротропного препарата в водном растворе транспортного средства 0,01 0,1 г/мл.A method of transporting neurotropic drugs to the brain by obtaining a solution of the drug in a vehicle with the subsequent introduction of this solution into the bloodstream, characterized in that a cyclodextrin and polyethylene oxide conjugate of the formula is used as a vehicle
where n 6 12;
m 6 7,
moreover, the concentration of the neurotropic drug in an aqueous solution of the vehicle is 0.01 to 0.1 g / ml
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU93043262A RU2094059C1 (en) | 1993-08-30 | 1993-08-30 | Method of transport of neurotropic preparation to brain |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU93043262A RU2094059C1 (en) | 1993-08-30 | 1993-08-30 | Method of transport of neurotropic preparation to brain |
Publications (2)
Publication Number | Publication Date |
---|---|
RU93043262A RU93043262A (en) | 1996-07-27 |
RU2094059C1 true RU2094059C1 (en) | 1997-10-27 |
Family
ID=20147064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU93043262A RU2094059C1 (en) | 1993-08-30 | 1993-08-30 | Method of transport of neurotropic preparation to brain |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2094059C1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1743907A1 (en) * | 2005-07-12 | 2007-01-17 | Gwangju Institute of Science and Technology | Conjugate of cyclodextrin and poly(oxyethylene), and process for preparation thereof |
US8110179B2 (en) | 2002-09-06 | 2012-02-07 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8497365B2 (en) | 2007-01-24 | 2013-07-30 | Mark E. Davis | Cyclodextrin-based polymers for therapeutics delivery |
US11464871B2 (en) | 2012-10-02 | 2022-10-11 | Novartis Ag | Methods and systems for polymer precipitation and generation of particles |
-
1993
- 1993-08-30 RU RU93043262A patent/RU2094059C1/en active
Non-Patent Citations (1)
Title |
---|
Zaise P., Kasparov S. Tawrine Functional neyrochemystry, physiology, cardiology, p. 237, 1990. * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8580244B2 (en) | 2002-09-06 | 2013-11-12 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8580243B2 (en) | 2002-09-06 | 2013-11-12 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8252276B2 (en) | 2002-09-06 | 2012-08-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8518388B2 (en) | 2002-09-06 | 2013-08-27 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8389499B2 (en) | 2002-09-06 | 2013-03-05 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8399431B2 (en) | 2002-09-06 | 2013-03-19 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8404662B2 (en) | 2002-09-06 | 2013-03-26 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8475781B2 (en) | 2002-09-06 | 2013-07-02 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8110179B2 (en) | 2002-09-06 | 2012-02-07 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US9550860B2 (en) | 2002-09-06 | 2017-01-24 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8314230B2 (en) | 2002-09-06 | 2012-11-20 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8580242B2 (en) | 2002-09-06 | 2013-11-12 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8680202B2 (en) | 2002-09-06 | 2014-03-25 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8603454B2 (en) | 2002-09-06 | 2013-12-10 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8609081B2 (en) | 2002-09-06 | 2013-12-17 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
EP1743907A1 (en) * | 2005-07-12 | 2007-01-17 | Gwangju Institute of Science and Technology | Conjugate of cyclodextrin and poly(oxyethylene), and process for preparation thereof |
US8497365B2 (en) | 2007-01-24 | 2013-07-30 | Mark E. Davis | Cyclodextrin-based polymers for therapeutics delivery |
US9610360B2 (en) | 2007-01-24 | 2017-04-04 | Ceruliean Pharma Inc. | Polymer drug conjugates with tether groups for controlled drug delivery |
US11464871B2 (en) | 2012-10-02 | 2022-10-11 | Novartis Ag | Methods and systems for polymer precipitation and generation of particles |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0441468B1 (en) | Gas-containing microparticles composed of polyaldehydes as contrast agents | |
DE602004009314T2 (en) | POLYSIALINSÄUREDERIVATE | |
DE69213272T2 (en) | Composition for inducing humoral anergy against an immunogen | |
DE69534990T2 (en) | CONTRAST AGENTS | |
US5141739A (en) | Delivery of x-ray contrast agents using receptor mediated endocytosis | |
RU2375384C2 (en) | New block copolymer, micellar preparation and anticarcinogenic agent containing micellar preparation as active component | |
JP3270592B2 (en) | Block copolymer-anticancer drug complex pharmaceutical preparation | |
JP6464087B2 (en) | Polyrotaxane and pharmaceutical composition | |
US4057617A (en) | Method of labeling proteins with technetium | |
JPS63146833A (en) | Method and drug for removing acquired glycosylated final product | |
Contin et al. | Advances in drug delivery, gene delivery and therapeutic agents based on dendritic materials | |
US20250099480A1 (en) | Methods and pharmaceutical compositions for treating candida auris in blood | |
DE1087791T1 (en) | INHIBIT OF XENOREACTIVE ANTIBODIES | |
US20220323591A1 (en) | Heparin nano drug carrier system loaded with amino anti-tumor drug and preparation method thereof | |
RU2094059C1 (en) | Method of transport of neurotropic preparation to brain | |
Gelb et al. | Poly (trehalose methacrylate) as an Excipient for Insulin Stabilization: Mechanism and Safety | |
Liu et al. | Synthesis, biodistribution, and imaging of PEGylated-acetylated polyamidoamine dendrimers | |
KR20120016032A (en) | Radial polymer compound containing iodine, preparation method thereof and contrast agent composition for CT comprising the same | |
US20240350506A1 (en) | Preparation of histone deacetylase inhibitor, and preparation method therefor and use thereof | |
WO2017188257A1 (en) | Methylated polyrotaxane and synthesis method for same | |
KR890007756A (en) | Method and material for preparing metal-labeled antibody solution | |
WO2010062570A2 (en) | COMPOSITIONS COMPRISING CAPTURE PEPTIDES FOR A β-AMYLOID PEPTIDE | |
CN1246059A (en) | Polymers | |
EP0821593A2 (en) | Conjugate of an active agent, a polyether and possibly a native protein regarded as acceptable by the body | |
US5955456A (en) | Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol |